Clinical inertia among patients with type 2 diabetes mellitus treated with DPP-4i and/or SGLT-2i

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Dipeptidyl Peptidase-4 Inhibitor 100%
• Patient with Type 2 Diabetes 100%
• Hemoglobin A1c 100%
• Diabetes 60%
• Metabolic Regulation 40%
• Oral Antidiabetic Agent 40%
• Glucagon Like Peptide 1 40%
• Adverse Outcome 20%
• Population Research 20%
• Glycemic Control 20%
• Specialist Care 20%
• Insulin-Related Peptide 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Dipeptidyl Peptidase IV Inhibitor 100%
• Hemoglobin A1c 83%
• Glucagon-Like Peptide-1 33%
• Population Study 16%
• Glucagon Like Peptide 1 Receptor Agonist 16%
• Adverse Outcome 16%